EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Integrated spatial and single-cell transcriptomics reveal PAK kinase as a therapeutic target in fibroblastic foci and dense fibrosis of idiopathic pulmonary fibrosis

Naoaki Watanabe, Masahiro Yoshida iD, Yuta Hirano, Shota Fujimoto, Sachi Matsubayashi, Takashi Ishiguro iD, Nobumasa Takahashi, Yoshihiko Shimizu, Noboru Takayanagi, Yoshinori Kawabata, Yutaro Mori, Koji Okamoto und 5 weitere

European Respiratory Journal · 2025-10 · 66 (4) · 2500022

DOI: 10.1183/13993003.00022-2025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 17.07.2025. Verfasst von Naoaki Watanabe und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, p21-Activated Kinases, Fibroblasts. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GlaxoSmithKline Japan, Japan Society for the Promotion of Science, Japanese Respiratory Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease characterised by progressive fibrosis of lung parenchyma. The histopathology of IPF exhibits temporal and spatial heterogeneity, including immature fibroblastic foci (FF) and densely collagenised fibrosis. FF serve as dynamic niches of pro-fibrotic fibroblasts and play a pivotal role in fibrosis progression and transition into dense fibrosis (DF). Here, we integrated single-cell RNA sequencing (scRNA-seq) with spatial transcriptomics to elucidate cellular heterogeneity and the novel cell type involved not only in FF formation, but also in DF development. We identified a novel myofibroblast population, WNT5A + CTHRC1 + myofibroblasts, enriched in both FF and DF regions, underscoring their pivotal role in fibrosis progression. Differential gene expression analysis revealed the activation of p21-activated kinase (PAK)2 in these fibrotic areas, including WNT5A + CTHRC1 + myofibroblasts. PAK inhibition significantly suppressed transforming growth factor-β-induced myofibroblast differentiation and collagen production in IPF-derived fibroblasts. Furthermore, in a bleomycin-induced lung fibrosis mouse model, intraperitoneal administration of the PAK inhibitor significantly attenuated fibrotic progression. This study highlights the therapeutic potential of PAK inhibition for IPF, particularly targeting pathogenic fibroblasts within both FF and DF regions. By leveraging spatial transcriptomics and scRNA-seq, we provide a comprehensive molecular and cellular atlas of FF and DF in IPF lung tissue, offering new insights into fibrosis progression and therapeutic intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary Fibrosisp21-Activated KinasesFibroblastsAnimalsMiceHumansSingle-Cell AnalysisMyofibroblastsTranscriptomeDisease Models, AnimalWnt-5a ProteinLungGene Expression ProfilingMaleBleomycinCell DifferentiationMice, Inbred C57BL

Substanzen

p21-Activated KinasesWnt-5a ProteinBleomycin

Autor:innen und Institutionen

  • Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
  • Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
  • N. Watanabe, M. Yoshida and Y. Hirano are co-first authors.
  • Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, Japan.
  • Department of Thoracic Surgery, Saitama Cardiovascular and Respiratory Center, Saitama, Japan.
  • Department of Pathology, Saitama Cardiovascular and Respiratory Center, Saitama, Japan.

ORCID-Profile: Masahiro Yoshida, Takashi Ishiguro

Förderung

  • GlaxoSmithKline Japan
  • Japan Society for the Promotion of Science
  • Japanese Respiratory Society
  • Mochida Memorial Foundation for Medical and Pharmaceutical Research
  • EVerMed Inc

Zitieren

APA

Watanabe, N., Yoshida, M., Hirano, Y., Fujimoto, S., Matsubayashi, S., Ishiguro, T., Takahashi, N., Shimizu, Y., Takayanagi, N., Kawabata, Y., Mori, Y., Okamoto, K., Minagawa, S., Kuwano, K., Araya, J., Yamamoto, Y., & Fujita, Y. (2025). Integrated spatial and single-cell transcriptomics reveal PAK kinase as a therapeutic target in fibroblastic foci and dense fibrosis of idiopathic pulmonary fibrosis. European Respiratory Journal, 66(4), 2500022. https://doi.org/10.1183/13993003.00022-2025

Vancouver

Watanabe N, Yoshida M, Hirano Y, Fujimoto S, Matsubayashi S, Ishiguro T, et al. Integrated spatial and single-cell transcriptomics reveal PAK kinase as a therapeutic target in fibroblastic foci and dense fibrosis of idiopathic pulmonary fibrosis. European Respiratory Journal. 2025;66(4):2500022. doi:10.1183/13993003.00022-2025

BibTeX
@article{Watanabe2025,
  author = {Watanabe, Naoaki and Yoshida, Masahiro and Hirano, Yuta and Fujimoto, Shota and Matsubayashi, Sachi and Ishiguro, Takashi and Takahashi, Nobumasa and Shimizu, Yoshihiko and Takayanagi, Noboru and Kawabata, Yoshinori and Mori, Yutaro and Okamoto, Koji and Minagawa, Shunsuke and Kuwano, Kazuyoshi and Araya, Jun and Yamamoto, Yusuke and Fujita, Yu},
  title = {Integrated spatial and single-cell transcriptomics reveal PAK kinase as a therapeutic target in fibroblastic foci and dense fibrosis of idiopathic pulmonary fibrosis},
  journal = {European Respiratory Journal},
  year = {2025},
  volume = {66},
  number = {4},
  pages = {2500022},
  doi = {10.1183/13993003.00022-2025}
}
Kostenlos starten →